Loading
Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours.
Octreotide (1988) controls carcinoid syndrome; PROMID (2009) showed octreotide LAR delays progression in midgut NETs (TTP 14.3 vs 6.0 months); CLARINET (2014) showed lanreotide improves PFS across enteropancreatic NETs (median not reached vs 18 months, HR 0.47). Standard first-line antiproliferative therapy for SSTR-positive grade 1-2 disease; also premedication against carcinoid crisis.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
SSTR2/5 agonism suppresses hormone secretion and proliferation; PROMID and CLARINET established the antiproliferative effect. Connects to Somatostatin receptor 2.
1.Binds SSTR2 on tumour cell
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Long-acting depot injections (Sandostatin LAR, Somatuline Depot, lanreotide generics) given in the clinic are Part B. Self-injected short-acting octreotide is Part D.
Covered for neuroendocrine tumours and carcinoid syndrome with prior authorisation; plans may prefer lanreotide (now multi-source) over Sandostatin LAR.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: somatostatin analogues. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
| Region | Year | Indication |
|---|---|---|
| US | 1988 | Carcinoid syndrome symptoms (octreotide) |
| US | 2014 | Unresectable GEP-NETs to improve PFS (lanreotide) |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Diarrhoea/steatorrhoea | 26% | - |
| Cholelithiasis | 10% | - |
| Hyperglycaemia | 5% | - |
CLARINET. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Somatostatin analogues" OR ABSTRACT:"Somatostatin analogues" OR TITLE:"octreotide, lanreotide" OR ABSTRACT:"octreotide, lanreotide" OR TITLE:"Sandostatin LAR" OR ABSTRACT:"Sandostatin LAR" OR TITLE:"Somatuline Depot" OR ABSTRACT:"Somatuline Depot" OR TITLE:"Octreotide" OR ABSTRACT:"Octreotide" OR TITLE:"Lanreotide" OR ABSTRACT:"Lanreotide") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Somatostatin analogues (octreotide, lanreotide), not a curated reading list.
Shares NETTER-1, PRRT (peptide receptor radionuclide therapy), Grade 3 well-differentiated neuroendocrine tumour, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4).
Shares Carcinoid syndrome and carcinoid heart disease, Telotristat ethyl, Somatostatin receptor 2, Neuroendocrine tumours.
Shares NETTER-1, PRRT (peptide receptor radionuclide therapy), Cancer of unknown primary, favourable subsets, Grade 3 well-differentiated neuroendocrine tumour.
Shares PRRT (peptide receptor radionuclide therapy), Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2, Small intestinal neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4), Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours.
Shares PRRT (peptide receptor radionuclide therapy), Lung neuroendocrine tumours (typical and atypical carcinoid), Somatostatin receptor 2, Pancreatic neuroendocrine tumours.